報價延遲最少15分鐘:2025/01/21 08:46 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
-- 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.39/-2.48
|
|
企業價值
3.43B
|
| 資產負債 |
|
每股賬面淨值
3.33
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
509.34M
|
|
每股收益
4.66
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/21 08:46 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatmentof solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derivesmajority of its revenue from the United States and rest from Germany, Japan and other markets. |